- Mali singer Traore child custody case postponed
- France mourns Mayotte victims amid uncertainy over government
- UK economy stagnant in third quarter in fresh setback
- Sweden says China denied request for prosecutors to probe ship linked to cut undersea cables
- African players in Europe: Salah leads Golden Boot race after brace
- Global stock markets edge higher as US inflation eases rate fears
- German far-right AfD to march in city hit by Christmas market attack
- Ireland centre Henshaw signs IRFU contract extension
- Bangladesh launches $5bn graft probe into Hasina's family
- US probes China chip industry on 'anticompetitive' concerns
- Biden commutes sentences for 37 of 40 federal death row inmates
- Clock ticks down on France government nomination
- 'Devastated' Australian tennis star Purcell provisionally suspended for doping
- Mozambique on edge as judges rule on disputed election
- Mobile cinema brings Tunisians big screen experience
- Philippines says to acquire US Typhon missile system
- Honda and Nissan to launch merger talks
- Police arrest suspect who set woman on fire in New York subway
- China vows 'cooperation' over ship linked to severed Baltic Sea cables
- Australian tennis star Purcell provisionally suspended for doping
- Asian markets track Wall St rally as US inflation eases rate fears
- Luxury Western goods line Russian stores, three years into sanctions
- Wallace and Gromit return with comic warning about AI dystopia
- Philippine military says will acquire US Typhon missile system
- Afghan bread, the humble centrepiece of every meal
- Honda and Nissan expected to begin merger talks
- 'Draconian' Vietnam internet law heightens free speech fears
- Israeli women mobilise against ultra-Orthodox military exemptions
- Asian markets track Wall St rally as US inflation eases rate worries
- Tens of thousands protest in Serbian capital over fatal train station accident
- Trump vows to 'stop transgender lunacy' as a top priority
- Daniels throws five TDs as Commanders down Eagles, Lions and Vikings win
- 'Who's next?': Misinformation and online threats after US CEO slaying
- Only 12 trucks delivered food, water in North Gaza Governorate since October: Oxfam
- Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
- Northern Superior Announces ONGold's Completion of Monument Bay and Domain Projects Acquisition in Manitoba
- ARIA Cybersecurity Solutions Partners with UFT to Protect Water Treatment Facilities from Dangerous Cyberattacks
- Clear Start Tax Named 2024 Orange County Register’s Top Workplaces for Exceptional Tax Resolution Service and Workplace Culture
- Ensysce Biosciences Regains Full Compliance with Nasdaq
- Tortoise Capital Completes Merger of Tortoise Power and Energy Infrastructure Fund, Inc. (NYSE: TPZ), Tortoise Pipeline & Energy Fund, Inc. (NYSE: TTP), and Tortoise Energy Independence Fund, Inc. (NYSE: NDP) and Conversion to Actively Managed ETF
- Tortoise Capital Completes Merger of Tortoise Energy Infrastructure Corp. (NYSE: TYG) and Tortoise Midstream Energy Fund, Inc. (NYSE: NTG)
- Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
- Datametrex Cancels RSUS
- South Star Battery Metals Announces Upsize of Non-Brokered Private Placement to Raise Up to US$3.20M, Extends Closing and Amended and Restated Stream Agreement
- Brightline Interactive Successfully Delivers A Scalable Immersive Simulation To A Global Government Service Integrator, Positioning Itself As A Leading Operating System For Processing And Visualizing Complex Information In 3D Space
- Urb NM is Named "Fastest Growing" Marijuana Brand in New Mexico
- Alset AI Broadens Investment Policy to Embrace Decentralized AI, Quantum AI, Quantum Computing, and Cryptocurrency Opportunities
- Strawberry Fields REIT Enters Into Agreement for Six Healthcare Facilities Located in Kansas
- NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
- Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
Strong trial results for Pfizer lung cancer drug
A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.
Lorlatinib, which is already approved and available under the brand name Lobrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Roughly half received lorlatinib while the rest received crizotinib, an earlier generation drug.
After five years of follow-up time, more than half of patients treated with lorlatinib did not see their cancer progress.
"We're talking about patients with advanced metastatic disease -- so this is actually a truly unprecedented finding," Pfizer's Despina Thomaidou told AFP.
Sixty percent of patients receiving lorlatinib, an oral one a day tablet, were alive without disease progression after five years compared to 8 percent on crizotinib.
"There is an 81 percent reduction in the risk of progression or death," added Thomaidou.
Lung cancer is the leading cause of cancer deaths globally.
NSCLC accounts for more than 80 percent of lung cancers, with ALK-positive tumors responsible for roughly five percent of NSCLC cases, with roughly 72,000 new cases each year worldwide.
ALK-positive NSCLC mostly affects younger patients and is largely decoupled from lifestyle indicators such as smoking. It is also very aggressive -- 25-40 percent of people with ALK-positive NSCLC develop brain metastases within the first two years.
Lorlatinib penetrates the blood-brain barrier better than prior generation medicines, said Thomaidou, and works to inhibit tumor mutations that drive resistance.
Side effects of lorlatinib included swellings, weight gain and mental health problems.
The results were published at the annual meeting of the American Society of Clinical Oncology and in the Journal of Clinical Oncology.
A.Malone--AMWN